Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051221 | 0.92 | SLC6A3 (0.43) | SLC6A3KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL17318414 | 0.87 | KDM4E (0.42) | KDM4ELMNATSHRALDH1A1L3MBTL1 | |
| SCHEMBL19051227 | 0.80 | KDM4E (0.37) | SLC6A3KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL17318443 | 0.77 | MMP13 (0.52) | ALDH1A1L3MBTL1MEN1KMT2AGAA | |
| SCHEMBL20285816 | 0.75 | RAB9A (0.45) | ALDH1A1L3MBTL1CYP3A4 | |
| SCHEMBL19051233 | 0.72 | MMP13 (0.48) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL10397228 | 0.71 | SLC6A3 (0.44) | SLC6A3SLC6A4 | |
| SCHEMBL2286519 | 0.71 | SLC6A3 (0.56) | SLC6A3KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL17318376 | 0.66 | SLC6A3 (0.44) | SLC6A3KDM4ELMNATSHRALDH1A1 | |
| SCHEMBL5252553 | 0.65 | ALDH1A1 (0.65) | TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10407382-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| EP-3152188-B1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926262-B2 | EP4 agonists as therapeutic compounds | ALLERGAN, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3152188-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015188152-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015188152-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407382-B2 | EP4 agonists as therapeutic compounds | PTGER4, PTGER1, PTGER3 | SLC6A3 3757/4885KDM4E 1756/4885LMNA 2795/4885 |
| US-20170183293-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | SLC6A3 3487/4885KDM4E 1549/4885LMNA 3396/4885 |
| US-20180170858-A1 | NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS | PTGER4, PTGER1, PTGER3 | SLC6A3 3487/4885KDM4E 1549/4885LMNA 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.